Compare Stocks

EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, natural gas liquids, and natural gas primarily in producing basins in the United States, the Republic of Trinidad and Tobago and internationally. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.

Falcon Oil & Gas Ltd., an oil and gas company, engages in the exploration, and development of unconventional oil and gas assets in Australia, South Africa, and Hungary. The company holds 22.5% interests in three exploration permits covering an area of approximately 1 million net acres in the Beetaloo Sub-basin, Northern Territory, Australia. It also holds a 100% interest in the technical cooperation permit covering an area of approximately 30,327.9 square kilometers in the southwest Karoo Basin, South Africa; and a 100% interest in the Makó production license covering an area of approximately 994.6 square kilometers in the Makó Trough located in south-eastern Hungary. The company was incorporated in 1980 and is headquartered in Dublin, Ireland.

Orca Exploration Group Inc. explores for, develops, produces, and sells petroleum and natural gas to the power and industrial sectors in Tanzania. The company principally holds interests in the Songo Songo natural gas field that includes two blocks covering an area of approximately 41,630 acres located to the south of Dar Es Salaam. It also holds oil and gas exploration and appraisal interests in Italy. The company was formerly known as EastCoast Energy Corporation and changed its name to Orca Exploration Group Inc. in April 2007. Orca Exploration Group Inc. was incorporated in 2004 and is based in Road Town, the British Virgin Islands.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.